Pacific Biosciences of California, Inc. (PACB)
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD Cowen Operator Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.
Pacific Biosciences Names Jim Gibson Chief Financial Officer
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.
Here's Why You Should Retain PacBio Stock in Your Portfolio Now
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
